

## **Valproate: updates to the HCP and patient guides.**

Dear Healthcare professional,

This letter is to inform you of **updates to the valproate HCP and patient guides** following changes in the prescribing information approved by Iraq Pharmacovigilance Center.

Information related to the risks of abnormal pregnancy outcomes in children exposed to valproate in utero, with new information on the risk of hearing impairment or deafness, updates related to the risk of ADHD have been included in these guides.

### **Call for reporting**

Any suspected adverse event should be reported to Sanofi on:

[Levant.pharmacovigilance@sanofi.com](mailto:Levant.pharmacovigilance@sanofi.com)

& to Iraq PV center on:

[iqphvc@yahoo.com](mailto:iqphvc@yahoo.com) and [iraqiphvc@moh.gov.iq](mailto:iraqiphvc@moh.gov.iq)

This medicinal product is subject to additional monitoring.

For any Medical enquiry please call +964 751 740 2599 or email us at [levant.medinfo@sanofi.com](mailto:levant.medinfo@sanofi.com)

### **Company contact point**

Sanofi Aventis Groupe  
Mecca Street, Al Hijaz Towers for Investment, 8th Floor  
PO BOX 922464, Amman 11192 – Jordan Tel: (962) 6 55 63 6 60  
[www.sanofi.com.jo](http://www.sanofi.com.jo)